Enterprise ▸ Industries ▸ Pharmaceuticals ▸Pilots ▸
Pharmaceuticals Pilot #4: Validation
Executive Summary
SagaPharma™ Pilot 4 ISPE-Guided Validation Package and Change Control
The Breakthrough
Pilot 4 delivers a breakthrough solution for one of the pharmaceutical industry’s most costly and time-consuming challenges: efficient, auditable, and risk-based validation of equipment, facilities, and software systems while maintaining strict confidentiality of proprietary test data.
The Problem Today
Validation cycles for new or modified manufacturing systems routinely take months to years, involving manual documentation, physical audits, and extensive paper trails.
Confidential test evidence (e.g., vendor protocols, raw execution data) must be shared with manufacturers and regulators, creating IP leakage risks and administrative burden.
Change control processes are slow and siloed, often triggering unnecessary re-validation and production delays.
Quality Risk Management (QRM) and Corrective/Preventive Actions (CAPA) remain disconnected across systems, increasing compliance risk and audit findings.
Manufacturers, vendors, and regulators all bear high costs in time, personnel, and lost production while patients wait longer for critical medicines.
What Pilot 4 Achieves
Using SagaChain’s open, programmable class tree and private enclave technology, Pilot 4 introduces an automated, governance-ready validation framework that is:
Fast & Transparent – Validation packages, requirements, risks, and verifications are created and tracked on-chain in real time.
Confidentiality-Preserving – Vendors upload sensitive test evidence into private enclaves; only cryptographic proofs of coverage are exposed for audit.
Automated Gating – Release of equipment or software is programmatically gated on objective coverage thresholds (e.g., ≥95% of requirements verified).
Integrated Change Control – Changes automatically trigger risk reassessment and targeted re-verification, with full audit trail.
Risk-Based & Connected – QRM priorities link directly to CAPA workflows (21 CFR 820) and feed continuous improvement.
Real-World Benefits
For Manufacturers & Validation Teams:
Reduce validation cycle time and cost by 30–50% through automation and elimination of manual reconciliation.
Achieve audit-ready records instantly, with immutable proof of coverage without exposing vendor IP.
Faster equipment release and change implementation, increasing production uptime.
For Equipment & Software Vendors
Submit confidential test data securely once; cryptographic attestations satisfy multiple customers without repeated disclosure.
Strengthen partnerships through demonstrable, verifiable quality evidence.
For Regulators & Auditors
Continuous, real-time visibility into validation status and coverage proofs.
Reduced on-site inspection burden through trusted, immutable records and automated risk signals.
For Patients & Global Health
Faster introduction of new therapies and capacity expansions.
Higher confidence in product quality through rigorous, transparent validation.
Projected total ecosystem value creation: $8–12 billion annually industry-wide through reduced validation delays, fewer audit findings, and accelerated time-to-market at 30% adoption by 2030.
Available now (on public development testnet) for review and testing
Pilots starts in ~90 days
Low-risk, high-impact, and ready for real validation packages and vendor evidence. We invite pharmaceutical manufacturers, CDMOs, equipment and software vendors, validation consultants, quality leaders, and regulators (FDA, EMA, PMDA, WHO, and others) to:
- Test the pilot with your own validation packages and change scenarios.
- Provide confidential evidence through enclaves and verify proof generation.
- Co-develop extensions (e.g., full GAMP 5 risk categories, ASTM E2500 integration, enhanced CAPA workflows).
- Join shared custodianship to prepare for global production launch.
More than a technical pilot…
The foundation for a faster, safer, and more trustworthy pharmaceutical manufacturing ecosystem.
The pharmaceutical community has a unique opportunity to take custodianship of this transformative validation framework.
By testing real-world packages, contributing confidential evidence workflows, and collaborating on refinements, you’ll accelerate a global launch that delivers massive operational efficiencies (30–50% faster validation, real-time auditability) and quality gains (reduced deviations, stronger vendor partnerships).
This open framework empowers manufacturers with rapid releases, vendors with IP protection, regulators with continuous oversight, and patients with faster access to medicines.